Johnson & Johnson Postpones Medical Devices & Diagnostics Review

NEW BRUNSWICK, N.J., Oct. 30, 2012  /PRNewswire/ -- Given the state of emergency in New Jersey due to Hurricane Sandy, Johnson & Johnson (NYSE: JNJ) announced that it will postpone the company's Medical Devices & Diagnostics business review for the investment community, which was scheduled for Thursday, Nov. 1st.  The company made the postponement decision to ensure the safety of its employees and expected attendees in the aftermath of the storm.  A new date for the business review will be scheduled for early 2013.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 129,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

SOURCE Johnson & Johnson

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.